Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat.
Abstract
OBJECTIVE
To determine if metformin improves markers of inflammation, thrombosis, and intrahepatic fat contents in children with uncomplicated
obesity.
METHODS
Obese children with normal glucose tolerance but elevated highly sensitive C-reactive protein (hsCRP) and/or fibrinogen concentrations
(>2 standard deviations) were randomized to structured diet/exercise or diet/exercise and metformin for 6 months. Blood samples,
dual energy X-ray absorptiometry data, and liver magnetic resonance images were obtained.
RESULTS
Forty-two of 66 recruited children (7-18 years) completed 6 months. Weight loss was modest but more pronounced in the metformin
group (-4.9 +/- 1.0 kg) than in the diet/exercise group (-1.7 +/- 1.1 kg, p<0.03), whereas hsCRP and fibrinogen decreased
more in the diet/exercise pubertal group. Baseline intrahepatic fat was high but decreased only in the diet/exercise (not
metformin) pubertal group.
CONCLUSIONS
Six months of metformin therapy improved weight loss and reduced abdominal adiposity, but did not enhance the beneficial effect
of diet and exercise on markers related to inflammation, thrombosis, or hepatic fat in obese children with normal glucose
tolerance.
Authors
Mauras N, DelGiorno C, Hossain J, Bird K, Killen K, Merinbaum D, Weltman A, Damaso L, Balagopal P
Institution
Division of Endocrinology, Diabetes and Metabolism, Nemours Children's Clinic, Jacksonville, FL32207, USA. nmauras@nemours.org
Source
Journal of pediatric endocrinology & metabolism : JPEM 25:1-2 2012 pg 33-40MeSH
Abdominal FatAdolescent
Biological Markers
C-Reactive Protein
Child
Female
Fibrinogen
Glucose Tolerance Test
Humans
Hypoglycemic Agents
Male
Metformin
Obesity
Weight Loss
Pub Type(s)
Journal ArticleRandomized Controlled Trial
Research Support, Non-U.S. Gov't
Language
eng
PubMed ID
22570948
Log In

